Azedose

Quick links to important sections

Azedose

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azedose

Property Description
Active ingredient Azithromycin
Form Film-coated tablet, Oral suspension
Pharmacological class Macrolide Antibiotic (Azalide)
General purpose To stop the growth of bacteria
Origin Semi-synthetic

Azedose is the commercial designation for the prescription medicine containing the active ingredient Azithromycin. This drug is classified as a powerful antibiotic and belongs to the Macrolide family, specifically the azalide subclass.


Azedose: Defining its Type and Identity as an Antibacterial Drug

Azedose is a single-ingredient, semi-synthetic anti-infective agent that is a synthetic derivative of the macrolide class. The active substance, Azithromycin, is structurally modified from older macrolides, enhancing its stability and biological properties. Azithromycin belongs to the pharmacological class of macrolide antimicrobials. A key differentiator for Azithromycin is its long half-life, a property allowing shorter, less frequent dosing schedules compared to many other antibiotic classes.


What is the General Purpose of Azedose?

The primary purpose of Azedose is to control and resolve a wide spectrum of infections caused by susceptible bacteria. It acts as a broad-spectrum anti-infective, helping the body clear bacterial illnesses by interrupting the infection's spread. The mechanism involves the drug binding to a specific site on the bacteria's 50S ribosomal subunit, which halts the bacteria's ability to synthesize essential proteins. Stopping the bacteria from growing and multiplying provides the body’s natural immune system with the opportunity to successfully eliminate the remaining, non-replicating pathogens.


Azedose: Available Forms and High-Level Composition

Azedose is formulated for systemic absorption and is typically administered via the oral route as a film-coated tablet or as a powder for oral suspension. The medicine is composed of the active ingredient, Azithromycin, combined with inactive pharmaceutical excipients. The availability of the oral suspension form is a deliberate differentiating feature, specifically targeting patient groups, such as children, who may struggle to swallow solid tablets, thereby ensuring broader access and accurate administration of the medication.

Regulatory References

  1. Azithromycin Mechanism of Action (NIH StatPearls)

What side effects are possible with Azedose?

Possible Side Effects and Safety Information

Azedose (azithromycin) is associated with both common, typically mild gastrointestinal side effects and serious, sometimes fatal, adverse reactions documented in regulatory warnings.

Common Adverse Reactions

The most frequently reported adverse reactions, affecting the gastrointestinal system, include diarrhea/loose stools, nausea, abdominal pain, and vomiting.

Serious and Clinically Significant Risks

Official regulatory documents emphasize several severe safety warnings that warrant caution, which include:

  • Cardiovascular Events: The drug can cause QT interval prolongation and cases of Torsades de Pointes, a potentially fatal irregular heart rhythm. Observational studies have suggested an increased short-term risk of acute cardiovascular death in adults.
  • Hepatotoxicity: Severe, and occasionally fatal, hepatotoxicity (liver damage) including hepatic necrosis and hepatic failure has been reported. The drug is contraindicated in patients with a history of cholestatic jaundice or liver dysfunction associated with prior use.
  • Hypersensitivity: Serious allergic reactions, including anaphylaxis, angioedema, and severe cutaneous adverse reactions like Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), have occurred.
  • Gastrointestinal Complications: Clostridioides difficile-Associated Diarrhea (CDAD) has been reported. In infants up to 42 days of life, Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported following treatment.

Population-Specific Safety Notes

Elderly patients may be more susceptible to the development of Torsades de Pointes. Caution is advised for patients with existing QT prolongation, low electrolyte levels (e.g., uncorrected hypokalemia), and those taking other QT-prolonging medications. The drug may also exacerbate muscle weakness in persons with Myasthenia Gravis.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Azedose (azithromycin) is generally expected to present as an intensified experience of known side effects affecting the gastrointestinal tract and auditory system.

Documented Overdose Presentations

Symptoms reported following an overdose include severe nausea, vomiting, and diarrhea. A specific, though typically reversible, manifestation is hearing loss.

Critical Overdose Risks

Cardiovascular risks are a serious concern following overdose or at high exposure levels. The drug is associated with a risk of QT interval prolongation and the rare, potentially fatal heart rhythm abnormality known as Torsades de Pointes.

Emergency Actions and Medical Attention

Situation Required Action (Label-Derived Phrasing Only)
Suspected or confirmed overdose Seek emergency medical help or call a poison control center immediately (e.g., 911/emergency services).
Management measures The immediate removal of unabsorbed drug is required, along with general supportive measures and continuous ECG monitoring to assess the cardiac risk.

Population-Specific Risk

In the context of the co-formulated opioid product, accidental ingestion of even one dose, particularly by a child, poses a severe risk of a fatal overdose due to the opioid component, which necessitates immediate emergency intervention.

Therapeutic Uses of Azedose

What Azedose Treats: Main Uses and Benefits

The primary purpose of Azedose is to address symptoms related to bacterial infections across several key domains. Azedose is commonly used in conditions that present with systemic or localized discomfort caused by susceptible bacteria.

Scope of Therapeutic Support

Azedose is relevant for managing symptoms related to bacterial conditions, including infections of the respiratory tract (pneumonia, acute bronchitis, sinusitis), certain sexually transmitted infections (STIs) like chlamydia, and uncomplicated bacterial skin infections. The medication is applied in clinical settings that involve acute or unstable symptom patterns. It is commonly used to help with easing the overall symptom burden and may also assist with maintaining functional stability.

It is relevant in conditions involving episodic or fluctuating manifestations, such as chronic lung conditions like COPD and Cystic Fibrosis (CF). Its use is applied during phases when symptoms become more noticeable due to acute infectious exacerbations in these patient groups.


Quick Fact: Support for Symptomatic Periods

Azedose is applied in addressing conditions that present with respiratory discomfort, which may assist with easing distressing symptoms like persistent cough, fever, and ear pain associated with acute infections, and supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus overview of Azithromycin

Eligibility and Restrictions for Use

Who Can and Cannot Use Azedose?

This section outlines the officially documented population eligibility rules for using Azedose (Azithromycin) based strictly on governmental regulatory information.

Absolute Contraindications

Azedose must not be used (is contraindicated) in patients who have a known hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide antibiotic. Use is also prohibited in patients with a history of cholestatic jaundice or hepatic dysfunction previously associated with azithromycin use.

Eligibility and Restrictions

Population Group Regulatory Status and Limitation
Pediatric Use Safety and effectiveness are not established for children under six months of age for most general indications.
Hepatic Impairment Caution is mandatory in cases of severe hepatic impairment, as the liver is the primary route of elimination.
Renal Impairment Caution should be exercised in patients with severe renal impairment (GFR < 10 mL/min).
Cardiac Risk Caution is required for patients with known QT prolongation or other proarrhythmic conditions, and those with Myasthenia Gravis.
Pregnancy/Lactation Should be used only if clearly needed (pregnancy); Caution is advised as it is excreted in breast milk (lactation).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Azedose based on its potential to affect cardiac rhythm and alter the concentrations of certain co-administered medicines.


Interaction Classifications

Classification Interacting Substance/Class
Contraindicated Pimozide, Ergot Derivatives (Not recommended due to theoretical ergotism risk)
Use with Caution Digoxin, Warfarin, Nelfinavir, Antacids, QT-Prolonging Drugs

Official Interaction Statements

  • Cardiac Risk: Azithromycin can prolong the QT interval on an electrocardiogram. Co-administration with other medicines that prolong the QT interval (e.g., Class IA and Class III antiarrhythmics) is restricted due to the additive pharmacodynamic effect and risk of ventricular arrhythmia.
  • Drug Exposure: Azithromycin is an inhibitor of the P-glycoprotein (P-gp) transporter. This can lead to increased serum concentrations of co-administered P-gp substrate medicines, such as Digoxin and Colchicine, necessitating monitoring.
  • Specific Restrictions: Co-administration with the HIV medicine Nelfinavir is documented to increase Azithromycin plasma levels (AUC and Cmax). Antacids containing aluminum or magnesium reduce the Azithromycin peak plasma concentration ( C max) and must be separated by an interval of at least 2 hours.
  • Population Note: The Colchicine interaction is contraindicated in patients with pre-existing renal or hepatic impairment due to heightened risk of toxicity.

Mechanism of Action

Inhibition of Essential Bacterial Protein Synthesis

Azedose (Azithromycin) initiates its primary pharmacodynamic action by targeting the essential replication machinery of susceptible bacteria. The molecule binds selectively to the 23S ribosomal RNA component of the bacterial 50S ribosomal subunit, specifically occupying the Nascent Peptide Exit Tunnel (NPET). This physical occupation inhibits the crucial translocation step of protein synthesis, thereby blocking the elongation of the polypeptide chain. This cessation of essential protein production results in the resolution of bacterial growth and subsequent proliferation, which permits host immune-mediated elimination of the non-replicating pathogens.


Modulation of Local Inflammation and Immune Cell Targeting

Beyond its core antibacterial role, Azithromycin influences the host response through the modulation of pro-inflammatory mediator production, such as specific cytokines. This secondary effect influences subsequent tissue processes. Crucially, the drug concentrates within host immune cells, specifically phagocytes (macrophages and neutrophils), using them as a vehicle for targeted delivery to the infected tissues. This intracellular accumulation leads to high concentrations delivered to inflamed tissues and contributes to the overall combined pharmacodynamic effect.

Dosage and Administration Information

How to Use Azedose: Official Administration Guidelines

Azedose (Azithromycin) is administered as a single daily dose via the oral or intravenous (IV) route, based on the specific formulation and treatment regimen. The instructions below summarize the drug's official labeled use.


Administration Scope and Forms

Feature Official Labeled Instruction
Administration Route Oral (film-coated tablets, oral suspension) or Intravenous (IV) Infusion.
Timing Relative to Food Tablets and standard oral suspension may be taken with or without food. The single-dose extended-release oral suspension must be taken on an empty stomach (1 hour before or 2 hours after a meal).
Special Preparation The powder for oral suspension requires reconstitution with water; the IV form requires dilution and slow infusion over a specified time (e.g., 60 minutes or longer).

Standard Dosing Regimens and Duration

Standard adult courses are typically short and once daily. Common oral regimens include the 1000 mg (1 g) single dose for certain infections, a 500 mg once-daily dose for three days, or a five-day regimen starting with 500 mg on Day 1, followed by 250 mg on Days 2 through 5.

  • Pediatric Dosing: For children over six months, the dose is generally determined based on body weight (mg/kg), with specific schedules like a 10 mg/kg dose on Day 1 followed by 5 mg/kg for four days, or a 30 mg/kg single dose.
  • IV to Oral Switch: IV therapy (e.g., 500 mg daily) is used for a minimum of two days and is followed by the oral form to complete a total treatment course, typically seven to ten days.

Procedural Notes

Oral suspension must be measured using the provided measuring device to ensure accuracy. If a dose of Azedose is missed, it should be taken as soon as remembered, unless it is nearly time for the next dose; in that event, the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azedose


Evidence for use in Respiratory Tract Infections

Research has examined Azedose in studies exploring bacterial infections that affect the breathing system, such as pneumonia, bronchitis, and sinusitis. Clinical studies have been conducted during periods of increased symptom activity to examine how symptoms evolved in the observed populations. These studies primarily focused on outcomes related to systemic or functional imbalance and outcomes describing episodic or acute changes.

The data show patterns related to outcomes monitored in the studies, including physical discomfort and outcomes linked to inflammatory or irritative states. For example, some studies monitored how symptoms evolved in the observed populations over defined time intervals. Research provides context but not individual predictions; results apply only to the populations studied, and findings describe group patterns, not personal outcomes.

Evidence for use in Skin and Soft Tissue Infections

Azedose was evaluated in research exploring conditions presenting with cycles of stability and flare-ups, specifically uncomplicated infections of the skin and underlying soft tissues. Research examined temporary physiological imbalance, and the findings describe patterns observed in the studies, focusing on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Studies conducted during periods of increased symptom activity reported how symptoms evolved in the observed populations. The findings contribute to understanding patterns related to systemic or functional imbalance monitored in the skin and tissue studies.


Long-term Studies and Follow-up

This section summarizes what is known and what remains unknown about the effects of Azedose after the initial study period. Follow-up durations were limited in most published research. Consequently, there is limited information for long-term outcomes, and the durability of response was not fully established by the studies. Research is ongoing to better understand any patterns that extend beyond the typical observation window.

Research Examining Special Populations

Research examined Azedose in studies involving special populations, but the extent of this research is highly variable. Research has explored its use in pediatric patients and older adults. However, data for certain groups, such as pregnant or breastfeeding populations and individuals with severe pre-existing conditions, remain insufficient. Subgroup findings are uncertain due to small numbers in these groups. Results apply only to the populations studied.

Key Studies & References

  1. Clinical Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by IDSA

Frequently Asked Questions (FAQ)

Common questions about Azedose (FAQ)


Q: Do the side effects of Azedose go away over time?

A: Official product information indicates that mild side effects, such as stomach upset or headache, are usually temporary and are generally expected to improve over the course of treatment or once the medication is stopped. If any side effects are severe or persistent, individuals should seek guidance from their healthcare provider.


Q: What types of over-the-counter pain relievers interact with Azedose?

A: Regulatory documents do not specifically restrict the use of all over-the-counter pain relievers. However, Azedose (Azithromycin) may cause some temporary side effects like headache or dizziness, and co-administration with other medicines may require review by a healthcare provider. Always inform your healthcare provider about every over-the-counter product being taken.


Q: Is Azedose generally safe for older adults (senior citizens)?

A: Official safety documents advise that caution is appropriate when Azedose is used in older adults. This is because this population may be more susceptible to the drug’s effect on the heart’s electrical activity (the QT interval), which is linked to a risk of an irregular heart rhythm.


Q: What are the official regulatory uses of Azedose?

A: According to the official product label, Azedose is indicated for treating mild to moderate bacterial infections caused by susceptible organisms. This includes specific conditions such as certain respiratory tract infections (like pneumonia and bronchitis), skin infections, and specific sexually transmitted diseases.


Q: How long does Azedose typically stay in the body after stopping use?

A: Official pharmacokinetics data indicates that Azedose has a prolonged half-life, meaning the drug is distributed widely throughout body tissues and is eliminated slowly. This characteristic is noted in regulatory information.


Q: Is Azedose available in a generic version?

A: Yes, the active ingredient in Azedose is Azithromycin. This substance is widely available as a generic prescription medicine, which may be offered as an alternative to the branded product.


Q: Does Azedose have any restrictions related to certain foods or juices (like grapefruit)?

A: The official interaction profile does not list restrictions for common foods or juices like grapefruit. However, the labeling for one specific form of the medicine—the extended-release oral suspension—indicates that it should be taken on an empty stomach to ensure appropriate absorption.


Q: Does Azedose affect blood pressure or heart rate?

A: Official safety information primarily highlights a risk related to the heart's electrical activity (QT prolongation), which can lead to a serious irregular heart rhythm. The regulatory documents advise considering the risk for patients with preexisting cardiac conditions.


Q: Does Azedose interact with common antibiotics?

A: Official documentation focuses on interactions with other drug classes that may prolong the QT interval or alter concentrations of medicines like Digoxin. Decisions about using Azedose with other antibiotics should be made based on guidance from a healthcare provider.


Q: Is it common for Azedose to be taken alongside other medications?

A: The official product label details several drug interactions that require careful consideration or are prohibited. This comprehensive interaction list suggests that co-administration of Azedose with other medicines is common, but any co-administration must be reviewed against the official interaction profile to manage potential risks.


Q: Does Azedose carry a black box warning from the FDA?

A: Azedose does not currently carry an official Black Box Warning (or Boxed Warning) from the FDA. However, the agency has issued communications and strengthened the Warnings and Precautions sections of the label regarding the potential risk of a life-threatening irregular heart rhythm.


Q: Is Azedose the same kind of drug as [Similar Drug Name]?

A: Azedose is classified in official documents as a Macrolide antibiotic, specifically belonging to the azalide subclass. The active substance is structurally modified from older macrolides, and its pharmacological properties define its use.


Q: Why do some people call Azedose a [Misconception/General Class] drug?

A: Official regulatory classification defines Azedose (Azithromycin) as a Macrolide Antibiotic, or azalide. The official label provides the exact pharmacological class to avoid confusion with other types of medicine and precisely define its mechanism of action.


Q: Can Azedose cause sleeplessness or affect sleep quality?

A: While insomnia is not listed as a common side effect in official documents, headache, dizziness, and fatigue are reported in post-marketing information. These effects may, in some individuals, indirectly affect their comfort or quality of sleep.


Q: Are headaches a common concern when starting Azedose?

A: Yes, regulatory documents list headache as a possible side effect of Azedose. Any new or unusually severe headache should be discussed with a healthcare provider.


Q: Does Azedose interact with supplements like vitamins or herbal products?

A: Regulatory documents consistently advise patients to inform their healthcare provider about all prescription and non-prescription products they are taking. This practice helps ensure the healthcare provider can accurately review the complete medicinal profile.


Q: Can Azedose affect my ability to drive or operate machinery?

A: Since Azedose may cause side effects such as dizziness or blurred vision in some individuals, caution is advised. The labeling advises caution when driving or operating complex machinery until an individual is aware of how the medication affects them.


Q: What is the difference between Azedose and a placebo in clinical trials?

A: In clinical research, Azedose is compared to a placebo (an inactive substance) to measure its effectiveness and to determine the frequency of side effects. This comparison helps regulatory bodies evaluate the drug’s overall profile prior to approval.


Q: Does Azedose require any special monitoring or regular blood tests?

A: While routine blood work is not generally required, Azedose has been linked to potential hepatotoxicity (liver damage). Official documents describe signs or symptoms that, if they occur, require a patient to be immediately evaluated for a liver problem.


Q: Is it normal to feel [vague sensation like 'tiredness' or 'dizziness'] when taking Azedose?

A: Yes, official documents indicate that fatigue and dizziness are among the reported side effects of Azedose (Azithromycin). Individuals who experience these or other side effects may want to discuss them with their healthcare provider.


Q: Where can I find the official prescribing information for Azedose?

A: Official prescribing information for Azedose, which includes the full prescribing label or the Summary of Product Characteristics (SmPC), is publicly available. These documents can be found on governmental drug databases such as DailyMed (NIH/FDA) and the websites of global regulatory agencies.


Q: Is Azedose classified as a controlled substance?

A: According to official regulatory schedules, Azedose (Azithromycin) is a prescription medicine but is not designated as a federally controlled substance in the United States.


Q: Do I need a new prescription every time for Azedose?

A: Azedose is classified as a prescription-only medicine (Rx-only) by regulatory bodies. This means that each time the medication is dispensed, it must be based upon a valid prescription provided by a licensed healthcare professional.


Q: What is the success rate of Azedose based on clinical trial data?

A: Official clinical trial results indicate that Azedose demonstrated effectiveness in treating the specific bacterial infections for which it is indicated. However, regulatory documents stress that these results apply to the patient populations studied. As with all medicines, the clinical effects observed in studies may not apply to every individual patient.


Q: Why is Azedose only available by prescription?

A: Azedose is classified as a prescription-only medicine because its use requires both a medical diagnosis and the supervision and instruction of a healthcare provider. This is necessary to ensure appropriate patient selection and to manage the potential for serious side effects and interactions.


Q: Does Azedose cause sensitivity to sunlight?

A: Yes, official product information indicates that Azedose (Azithromycin) may cause some patients to experience increased sensitivity of the skin to sunlight, also known as photosensitivity.


Q: Are there known cases of people building tolerance to Azedose over time?

A: Regulatory information does not address the concept of patient tolerance to the drug. However, official usage guidelines strongly recommend that Azedose only be used to treat infections caused by susceptible bacteria to limit the development of drug-resistant bacteria over time.


Q: What are the possible vision-related side effects of Azedose?

A: Vision-related effects, such as blurred vision, have been reported in post-marketing surveillance for Azedose. Vision changes, if noticed, should be discussed with a healthcare provider.

How should Azedose be stored and disposed of?

How to Store and Dispose of Azedose (Azithromycin)

The storage and disposal of Azedose must follow official regulatory requirements to ensure stability and safety.


Storage Conditions

Azithromycin tablets and the dry powder for suspension must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept in its original, tightly closed container and protected from moisture.

The reconstituted oral suspension has limited stability and must be discarded after 10 days or upon completing the course of therapy. The liquid suspension must not be frozen.

All forms of Azedose must be stored out of the sight and reach of children.


Disposal Requirements

Unused or expired medicine should be disposed of through a drug take-back program. If one is unavailable, it may be mixed with an undesirable substance and placed in a sealed container in the household trash. It must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azedose found in:

A-Z Index: